Isis rises on thrombosis data, R&D update
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals gained 7.5% to close at $24.95 per share on 22 May after the Carlsbad, California-based company said its Factor XI inhibitor ISIS-FXIRx reduced venous thrombolic events (VTEs) following total knee replacement surgery in a 300-patient Phase II clinical trial.